Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene (6160 HK)</a> reported 2Q25 revenues of $1.3B, up 42% YoY (1H25 Revenue: $2.4B, up 45%), driven primarily by growth in Brukinsa sales in the U.S. and Europe.</li>
<li>In 2Q25, U.S. sale of Brukinsa was $684M, up 43% YoY. For three consecutive quarters now, Brukinsa outpaced its closest competitor Calquence which reported US revenue of $583M in 2Q25.</li>
<li>BeiGene now expects 2025 revenue to be in the range of $5.0–5.3B (up 29–39% YoY) compared to the previous revenue guidance of $4.9–5.3B.</li>
</ul>



BeiGene (6160 HK) reported 2Q25 revenues of $1.3B, up 42% YoY (1H25 Revenue: $2.4B, up 45%), driven primarily by growth in Brukinsa sales in the U.S. and Europe.
In 2Q25, U.S. sale of Brukinsa was $684M, up 43% YoY. For three consecutive quarters now, Brukinsa outpaced its closest competitor Calquence which reported US revenue of $583M in 2Q25.
BeiGene now expects 2025 revenue to be in the range of $5.0–5.3B (up 29–39% YoY) compared to the previous revenue guidance of $4.9–5.3B.


BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>AbbVie recently reported its financial results for the second quarter of 2025, showcasing both achievements and challenges.</li><li>AbbVie posted an adjusted earnings per share of $2.97, which surpassed their guidance midpoint by $0.11.</li><li>Total net revenues came in at $15.4 billion, exceeding expectations by over $400 million.</li></ul>

AbbVie recently reported its financial results for the second quarter of 2025, showcasing both achievements and challenges.AbbVie posted an adjusted earnings per share of $2.97, which surpassed their guidance midpoint by $0.11.Total net revenues came in at $15.4 billion, exceeding expectations by over $400 million.

AbbVie’s Skyrizi Surge: The Blockbuster Drug Defying Expectations & Dominating New Markets!

<ul><li>AbbVie’s reported discussions to acquire Gilgamesh Pharmaceuticals for approximately $1 billion mark the latest twist in the company’s aggressive M&A strategy, as it seeks new engines of growth beyond its ex-Humira platform.</li><li>Just days after raising its 2025 guidance on the strength of Skyrizi, Rinvoq and Vyalev — and outlining an $8-year runway driven by oncology, neuroscience, immunology and aesthetics — AbbVie is doubling down on psychiatric innovation.</li><li>Gilgamesh, a privately held developer of psychoplastogen-based therapies, has already joined forces with AbbVie on a co-development pact that could funnel up to $1.95 billion in milestone payments into novel mood-disorder treatments.</li></ul>

AbbVie’s reported discussions to acquire Gilgamesh Pharmaceuticals for approximately $1 billion mark the latest twist in the company’s aggressive M&A strategy, as it seeks new engines of growth beyond its ex-Humira platform.Just days after raising its 2025 guidance on the strength of Skyrizi, Rinvoq and Vyalev — and outlining an $8-year runway driven by oncology, neuroscience, immunology and aesthetics — AbbVie is doubling down on psychiatric innovation.Gilgamesh, a privately held developer of psychoplastogen-based therapies, has already joined forces with AbbVie on a co-development pact that could funnel up to $1.95 billion in milestone payments into novel mood-disorder treatments.

AbbVie’s $1 Billion Bet On Gilgamesh: The Neuroscience Acquisition That Could Change Everything!

Equity Capital Markets

Ascentage Pharma / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ascentage-pharma-group-inter" target="_blank" data-smartkarma-citation="entities:27824:1" rel="noopener">Ascentage Pharma Group Corp (6855 HK)</a> announced the placement of 22M shares for subscription at HK$68.6 per share, representing 8% discount to last trading price before announcement.</li>
<li>The company intends to use the net proceeds for commercialization efforts, global clinical development to advance the core pipeline candidates and for infrastructure and working capital to strengthen global operations.</li>
<li>The launch of lisaftoclax in China followed by eventual approval olverembatinib in US would be the near-term triggers for the company.</li>
</ul>



Ascentage Pharma Group Corp (6855 HK) announced the placement of 22M shares for subscription at HK$68.6 per share, representing 8% discount to last trading price before announcement.
The company intends to use the net proceeds for commercialization efforts, global clinical development to advance the core pipeline candidates and for infrastructure and working capital to strengthen global operations.
The launch of lisaftoclax in China followed by eventual approval olverembatinib in US would be the near-term triggers for the company.


Ascentage Pharma (6855 HK): Placement Priced Reasonably; Pipeline Leads to Niche Market Opportunity

<ul><li>AbbVie Inc. recently reported its results for the first quarter of 2025, showcasing strong performance across various therapeutic areas.</li><li>The company's adjusted earnings per share were $2.46, surpassing the guidance midpoint by $0.10.</li><li>Total net revenues stood at over $13.3 billion, a remarkable increase of roughly $550 million beyond expectations.</li></ul>

AbbVie Inc. recently reported its results for the first quarter of 2025, showcasing strong performance across various therapeutic areas.The company's adjusted earnings per share were $2.46, surpassing the guidance midpoint by $0.10.Total net revenues stood at over $13.3 billion, a remarkable increase of roughly $550 million beyond expectations.

AbbVie’s Bold Obesity Play Could Up Its Game In The GLP-1 Domain—Here’s What You Need to Know!

United States

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, Hepatitis C, women's health, oncology, and neuroscience. AbbVie also offers treatments for diseases including Multiple Sclerosis, Parkinson's, and Alzheimer's disease.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Abbvie Inc (ABBV US)

BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision

Beigene announced positive topline results from Phase 1/2 study of sonrotoclax, a next-generation and potentially best-in-class investigational...

Tina Banerjee

AbbVie’s Skyrizi Surge: The Blockbuster Drug Defying Expectations & Dominating New Markets!

AbbVie recently reported its financial results for the second quarter of 2025, showcasing both achievements and challenges. AbbVie posted an...

Baptista Research

AbbVie’s $1 Billion Bet On Gilgamesh: The Neuroscience Acquisition That Could Change Everything!

AbbVie’s reported discussions to acquire Gilgamesh Pharmaceuticals for approximately $1 billion mark the latest twist in the company’s aggressive...

Baptista Research

Ascentage Pharma (6855 HK): Placement Priced Reasonably; Pipeline Leads to Niche Market Opportunity

Ascentage Pharma is placing 22M shares at HK$68.6/share, 8% discount to last trading price. Proceeds will fund commercialization efforts and...

Tina Banerjee

AbbVie’s Bold Obesity Play Could Up Its Game In The GLP-1 Domain—Here’s What You Need to Know!

AbbVie Inc. recently reported its results for the first quarter of 2025, showcasing strong performance across various therapeutic areas. The...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

BeiGene (6160 HK): Brukinsa Extend Lead in US, Robust Pipeline, Positive Guidance Revision

Beigene announced positive topline results from Phase 1/2 study of sonrotoclax, a next-generation and potentially best-in-class investigational...

Tina Banerjee

AbbVie’s Skyrizi Surge: The Blockbuster Drug Defying Expectations & Dominating New Markets!

AbbVie recently reported its financial results for the second quarter of 2025, showcasing both achievements and challenges. AbbVie posted an...

Baptista Research

AbbVie’s $1 Billion Bet On Gilgamesh: The Neuroscience Acquisition That Could Change Everything!

AbbVie’s reported discussions to acquire Gilgamesh Pharmaceuticals for approximately $1 billion mark the latest twist in the company’s aggressive...

Baptista Research

Ascentage Pharma (6855 HK): Placement Priced Reasonably; Pipeline Leads to Niche Market Opportunity

​Ascentage Pharma is placing 22M shares at HK$68.6/share, 8% discount to last trading price. Proceeds will fund commercialization efforts and...

Tina Banerjee

AbbVie’s Bold Obesity Play Could Up Its Game In The GLP-1 Domain—Here’s What You Need to Know!

AbbVie Inc. recently reported its results for the first quarter of 2025, showcasing strong performance across various therapeutic areas. The...

Baptista Research

Ascentage Pharma is placing 22M shares at HK$68.6/share, 8% discount to last trading price. Proceeds will fund commercialization efforts and...